Why “Easy to Use” Is Not Evidence of Low Medical-Device Use Risk
This series examines human factors engineering and usability engineering as medical-device safety disciplines. Its central question is simple but demanding: when someone says that a device is “easy to use,” what evidence would justify the stronger conclusion that using it carries low risk? The answer cannot rest on comfort or speed alone. It has to connect the device’s users, the conditions in which they work, the interface they must understand and control, and the consequences of getting a critical task wrong.
That distinction matters because medical devices do not merely help people complete actions. They can determine a dose, deliver therapy, display a patient’s status, maintain a life-supporting condition, or signal that an urgent response is needed. An interaction can feel smooth and still contain a rare pathway to serious harm. Conversely, a device can demand effort without making its most dangerous tasks unsafe. The relevant question is not whether every interaction feels effortless. It is whether the design helps the intended users perform the tasks that matter, under the conditions that matter, without errors that could compromise care.
A simulation-based study of an infusion pump makes the tension concrete. The nurses in the study generally regarded the pump as user-friendly and reported relatively low mental workload and perceived likelihood of programming errors. Yet the evaluation also identified difficult operations, near misses, and operation failures. The point is not that a favorable impression has no value. It is that the impression cannot carry the whole safety judgment.
Ease is not the same as use safety
The FDA’s human-factors guidance uses a different starting point from ordinary product reviews. It treats human factors engineering, or HFE, and usability engineering, or UE, as processes intended to maximize the likelihood that a medical device will be safe and effective for its intended users, uses, and use environments. The guidance does acknowledge that ease of use, efficiency, and user satisfaction can improve a product. But its primary concern is whether use errors that could cause harm or degrade treatment are eliminated or reduced as far as possible.
That difference changes what the word “easy” can mean. In an everyday setting, ease might mean that a person learns a control quickly, needs little effort, or enjoys the interaction. In a medical setting, those properties can be useful signals about design quality, but they do not answer the safety question by themselves. A user may feel confident while overlooking a warning. They may complete a sequence quickly while entering the wrong value. They may recover from a mistaken action before harm occurs without realizing that the recovery was necessary. A survey of confidence would not show all of those events, and a completion time would reveal very little unless speed itself is clinically important.
The FDA defines a use error as an action or inaction that differs from what the manufacturer expected, produces a result different from what the user expected, is not caused solely by device failure, and did or could result in harm. This definition keeps attention on the relationship among the user’s action, the device’s design, and the consequence. It is not a synonym for clumsiness, nor does it treat every departure from an ideal sequence as equally serious.
A critical task is narrower still: it is a task that, if performed incorrectly or not at all, would or could cause serious harm to the patient or user, including compromised medical care. That definition explains why a general statement such as “most participants liked the device” is weak evidence for a high-consequence task. The overall impression averages together actions that may be harmless with actions that may determine whether therapy starts, stops, or proceeds correctly.
Risk also has two dimensions. The guidance describes it as the combination of the probability that harm occurs and the severity of the potential harm. But it cautions that the probability of use error is hard to estimate because many errors are not anticipated until people use the device and their behavior is observed. A low-frequency error may therefore deserve serious attention when its consequence is severe. A smooth demonstration does not make a severe pathway disappear merely because no participant happened to take it during a short session.
This is why the FDA’s framework does not treat a usability process as a certificate. The 2026 guidance is explicitly nonbinding: it describes the agency’s current recommendations, not a legally enforceable guarantee that a device is safe. It provides a disciplined way to find and reduce use-related risk. The device-specific conclusion still depends on what was tested, who used it, what they were asked to do, what happened, and how the remaining risk was judged.
A medical device is more than its controls
The safety problem becomes clearer when a medical device is viewed as a system rather than as a collection of buttons or screens. The FDA identifies three connected parts: the device users, the device use environments, and the device user interface. The interface includes every point at which the user and device interact. Displays and physical controls are obvious examples, but so are alarms, feedback, connection points, packaging, labels, instructions for use, training, and the logic that determines how the device responds.
The user’s interaction with the system is cyclical. They perceive information, interpret it, make a decision, act on the device, and receive feedback. That feedback may begin another cycle. At each stage, the system can support a correct action or create an opportunity for error. Information may be difficult to notice. A display may be readable in a quiet room but not under glare or distraction. A control may operate in a direction that conflicts with a user’s experience of similar devices. A response may be technically correct but arrive in a form that the user does not understand.
The user is also part of the safety context. Relevant characteristics can include vision, hearing, dexterity, strength, memory, health status, literacy, language, experience with similar devices, knowledge of the particular device, and willingness or ability to learn. These are not reasons to blame a person for failing to adapt. They are design facts that determine whether the intended user can perceive, understand, and perform the required action.
The environment can change the same interaction without changing the hardware. The FDA points to conditions such as low or high lighting, noise that masks an alarm, several similar devices in one room, clutter and distraction, or movement in a vehicle. A home user may be interrupted. A clinician may be handling several demands at once. A patient’s condition may affect attention or dexterity. If a device depends on a capability that the real environment predictably impairs, then the environment is part of the use-related hazard.
This model also explains why “intuitive” is an unstable safety claim. Intuitiveness usually means that an action matches a person’s expectations. Expectations come from prior devices, workplace habits, language, symbols, and training. They vary across users. A control that behaves as expected to one person can violate the learned convention of another. The more consequential the action, the less acceptable it is to treat an expectation match as proof that the action will be safe in every relevant setting.
The system view prevents a second mistake: assuming that an instruction can repair any design weakness. Instructions and training are part of the interface, but they depend on access, attention, memory, interpretation, and retention. The FDA therefore says that modifying the device or its user interface is generally more effective than relying on revised labeling or training alone. That is not because information is worthless. It is because a safety control that operates at the moment of action can be more dependable than a warning that must first be remembered and applied.
What would count as evidence?
A stronger safety judgment begins by asking what could go wrong and what harm could follow, not by asking whether the interface looks clean or receives favorable ratings. The first step is to identify use-related hazards: situations in which the user’s abilities, expectations, environment, or the interface’s information and controls could lead to an unsafe action. Those hazards are then connected to tasks and use scenarios. A task becomes critical when an error or omission could cause serious harm.
That work can begin analytically. Teams can break a workflow into steps, examine possible failure modes, reason backward from a hazardous outcome, review known problems with similar devices, or ask experts to inspect the interface. Such methods are valuable because they make risk visible early, when redesign is easier. But they do not include actual users performing realistic work. The FDA specifically warns that use errors can surprise analysts, which is why simulated-use testing is needed to confirm and extend the analytical picture.
The next layer is control. A manufacturer may change the interface so that a dangerous action is impossible, harder to select, or easier to detect. It may add a protective mechanism or an alert. It may also use labeling and training for hazards that cannot otherwise be addressed. During formative evaluation, representative users interact with a developing design so the team can discover unexpected problems, make changes, and evaluate those changes before the final validation test. A positive result is therefore more meaningful when it sits inside a visible cycle of hazard identification, design response, and rechecking.
Final validation asks a still narrower question: can the intended users use the final interface safely and effectively for the intended use under expected conditions? The evidence needs to include the critical tasks, representative users, realistic conditions, and a test setup that allows people to behave as independently as they would in actual use. It should capture errors even when users do not recognize them. It should also consider close calls, repeated attempts, confusion, knowledge of essential warnings, and the causes of observed problems. A participant’s positive opinion can complement these observations; it cannot replace them.
So what can the phrase “easy to use” legitimately tell us? It may suggest that users encounter little friction in some interactions. It may help identify an interface that is more acceptable, learnable, or efficient. It may be one useful input to design decisions. But it does not identify which tasks are critical, whether users understood essential information, how they performed under realistic conditions, or whether a remaining error could cause serious harm. Those questions require evidence tied to the device’s actual hazards and users.
The practical replacement for “this device is easy to use” is more specific: these intended users performed these critical tasks, in these relevant conditions, with this final interface and this level of support; the evaluation observed these errors and close calls; the design changes addressed their causes; and the remaining risk was judged in relation to possible harm. That is a longer statement because safety evidence has more parts than an impression.
The next question, then, is how users, environments, and interfaces combine to produce a particular hazard—and how a broad concern becomes a critical task that can be analyzed and tested. That shift from a general feeling to a consequence-bearing interaction is where a medical-device usability claim begins to acquire evidentiary meaning.